Compare · AZTR vs NVO
AZTR vs NVO
Side-by-side comparison of Azitra Inc (AZTR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZTR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 49703.9x AZTR ($3.8M).
- Over the past year, AZTR is down 88.5% and NVO is down 44.9% - NVO leads by 43.6 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 0 for AZTR).
- Company
- Azitra Inc
- Novo Nordisk A/S
- Price
- $0.22-2.67%
- $43.38+1.38%
- Market cap
- $3.8M
- $191.15B
- 1M return
- -0.82%
- -7.73%
- 1Y return
- -88.51%
- -44.92%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2023
- News (4w)
- 8
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AZTR
- SEC Form DEFA14A filed by Azitra Inc
- Azitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
- SEC Form EFFECT filed by Azitra Inc
- SEC Form DEFA14A filed by Azitra Inc
- Azitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting
- SEC Form S-1 filed by Azitra Inc
- Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
- SEC Form 10-Q filed by Azitra Inc
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care